GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sareum Holdings SAR.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

14.50p

-3.33%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Sareum Holdings — daily SAR

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Sareum Holdings on TradingView ↗
Market value
£17.8m
Last close × shares
Volume
79.2k
Shares, 9 Nov 2026

About Sareum Holdings

Its shares trade on LSE under the ticker SAR.L. It has been listed since 11 October 2004. In the fiscal year to 30 June 2020, it reported revenue of £47,204 and a net loss of £985,913. At that date it held total assets of £2.0m and shareholders' equity of £1.8m.

Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. The company is headquartered in Cambridge, Cambridgeshire. The company went IPO on 2004-10-11. The firm's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.

Figures and description from our data supplier, not checked against the company's own report.

More about Sareum Holdings →

Latest on Sareum Holdings

Our reporting

We have not reported on Sareum Holdings yet.

Next results

31 Mar 2027

Due on 31 Mar 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Sareum Holdings's ticker?

Sareum Holdings trades as SAR.L on LSE, under ISIN GB00BMC3RJ87.

What was Sareum Holdings's last closing price?

14.50p on 9 Nov 2026. The figure is in GBp and is never converted.

When does Sareum Holdings next report results?

Results are expected on 31 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.